Skip to main content
. Author manuscript; available in PMC: 2024 Mar 21.
Published in final edited form as: N Engl J Med. 2023 Jul 17;389(12):1096–1107. doi: 10.1056/NEJMoa2305032

Figure 1. Screening, Randomization, and Follow-up.

Figure 1

The modified intention-to-treat population included randomly assigned participants who received at least one dose of solanezumab or placebo and underwent assessment for the primary end point. Participants who completed visit 66 (target, 240 weeks) were considered to have completed the double-blind phase. ApoE denotes apolipoprotein E, Covid-19 coronavirus disease 2019, and PET positron-emission tomography.